***Curis Inc.-Biorakete an der NASDAQ*** - 500 Beiträge pro Seite

[can2]

da geht bald was! WKN:940909 www.curis.com


Curis Announces Key Management Promotions
Michael Gray Appointed COO and Dr. Changgeng Qian Promoted to the

Position of Vice President, Discovery and Preclinical Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 20, 2006--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, today announced recent promotions within its management team infrastructure. The changes were made to better align the management structure with Curis' ongoing strategy of deemphasizing early stage discovery research and seeking instead to develop proprietary later stage preclinical and, ultimately, clinical assets. The first such later stage program is a platform of proprietary cancer programs that target multiple validated cancer pathways. This platform is currently in preclinical testing and Curis expects to select the first lead clinical candidate in early 2007 and file an Investigational New Drug (IND) application during the second half of 2007.

Management Promotions

Michael P. Gray, who most recently held the position of Senior Vice President of Finance and Chief Financial Officer, will assume the additional role of Chief Operating Officer, while retaining the responsibilities and title of Chief Financial Officer. Gray will continue to have primary responsibility over a majority of Curis' administrative functions and will now have a greater role in aligning Curis' promising drug development programs with the company's overall corporate objectives and operating budget.

"Mike Gray has been an important part of the Curis team and has consistently demonstrated strong management and leadership skills during his tenure," said Dan Passeri, President and Chief Executive Officer of Curis. "He has provided solid financial and administrative oversight throughout his three years as Curis' Chief Financial Officer and was also instrumental in implementing various aspects of our recent entry into China. I will be looking to Mike to lead the coordination of the company's drug development and administrative efforts as we seek to move our drug programs into later stages of development in a highly effective and cost-efficient manner."

In addition, Curis recently promoted Dr. Changgeng Qian to the position of Vice President, Discovery and Preclinical Development. Dr. Qian joined Curis in 2001, bringing more than 25 years of academic and industrial experience in drug discovery, including pharmacokinetics, drug metabolism, efficacy evaluation, experimental disease model development and drug safety assessment. He has played key roles in the discovery and development of several drug candidates, including cancer and central nervous system indications at CytoMed, Inc., LeukoSite, Inc., and Millennium Pharmaceuticals, Inc.

Noted Passeri, "Dr. Qian brings tremendous experience and scientific leadership to his new role. He has been an invaluable asset to Curis, both in his guidance surrounding Curis' programs under collaboration, and in his leadership in directing Curis' wholly-owned and proprietary multi-targeted inhibitor (MTI) programs. We are extremely pleased to have someone of Dr. Qian's caliber leading these scientific efforts."

[can2]

Tue, Dec 26, 2006

FILING Report of unscheduled material events or corporate changes - Form 8-K

Wed, Dec 20, 2006

8:04 AM Curis Announces Key Management Promotions - Business Wire
FILING Report of unscheduled material events or corporate changes - Form 8-K

Thu, Nov 30, 2006

8:03 AM Curis to Present at Wall Street Analyst Forum Investor Conference - Business Wire

[can2]

Thu, Jan 04, 2007

FILING Annual statement of changes in beneficial ownership of securities - Form 5

wieso ist heute auf einmal so ein deutlich höheres volumen??

[can2]

Seitwärtsbewegung hält schon ziemlich lange an und die nachfrage im geld wird höher...
Börse
NASDAQ

Aktuell
1,34 USD

Zeit
26.01.07 19:11

Diff. Vortag
+3,88 %

Tages-Vol.
72.644,87

Gehandelte Stück
54.560

Geld
1,34

Brief
1,35

Zeit
26.01.07 19:11

Spread
0,74%

Geld Stk.
6.300

Brief Stk.
1.500

Schluss Vortag
1,29

Eröffnung
1,2801

Hoch
1,36

Tief
1,27

52W Hoch
2,82

52W Tief
0,95

Split
--

[can2]

Nachfrage steigt! seit monaten seitwärtsbewegung, gute news auf deren internetseite...und und und...wann gehts los?
Börse
NASDAQ

Aktuell
1,39 USD

Zeit
31.01.07 19:05

Diff. Vortag
+5,30 %

Tages-Vol.
100.601,83

Gehandelte Stück
73.504

Geld
1,37

Brief
1,39

Zeit
31.01.07 19:16

Spread
1,44%

Geld Stk.
4.300

Brief Stk.
400

[can2]

klettert und klettert in mini steps?
Börse
NASDAQ

Aktuell
1,47 USD

Zeit
02.02.07 15:30

Diff. Vortag
+2,80 %

Tages-Vol.
10.279,71

Gehandelte Stück
6.993

Geld
1,44

Brief
1,46

[can2]

February 1, 2007 - 8:04 AM EST

close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

CRIS 1.51 0.08

Today 5d 1m 3m 1y 5y 10y



Curis to Release Year End and Fourth Quarter 2007 Financial Results and Hold Conference Call on February 14, 2007
Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, will release its year end and fourth quarter financial results on Wednesday, February 14, 2007 before the market opens. The Company will also hold a conference call at 10:00 a.m. Eastern on the 14th to discuss the financial results, progress of its therapeutic product development programs, and additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.

To access the live conference call, please call [phone] from the United States and Canada or [phone] from additional International locations, shortly before 10:00 A.M. The conference ID number is 81229487. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Wednesday, February 28, 2007. To access the replay, please call [phone] from the United States and Canada or [phone] from other locations and reference the conference ID number 50926099.

[can2]

Noch 1 Woche, dann kommen die Fakten auf den Tisch! Der Kurs ist seit Wochen stabil, sollten positive news kommen, kann es schnell rauf gehen, noch ist curis meiner meinung sehr günstig bei

February 1, 2007 - 8:04 AM EST

Curis to Release Year End and Fourth Quarter 2007 Financial Results and Hold Conference Call on February 14, 2007
Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, will release its year end and fourth quarter financial results on Wednesday, February 14, 2007 before the market opens. The Company will also hold a conference call at 10:00 a.m. Eastern on the 14th to discuss the financial results, progress of its therapeutic product development programs, and additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.

To access the live conference call, please call [phone] from the United States and Canada or [phone] from additional International locations, shortly before 10:00 A.M. The conference ID number is 81229487. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Wednesday, February 28, 2007. To access the replay, please call [phone] from the United States and Canada or [phone] from other locations and reference the conference ID number 50926099.

About Curis, Inc.

Curis is a drug discovery and development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease, hair growth regulation and cardiovascular disease. For more information, please visit www.curis.com.


Curis, Inc.
Michael P. Gray, 617-503-6632
CFO/COO
[e-mail]
or
For Curis, Inc.
Jenny Viscarolasaga, 617-503-6658
[e-mail]



Source: Business Wire (February 1, 2007 - 8:04 AM EST)

News by QuoteMedia

[can2]

sorry...bei:
Börse
NASDAQ

Aktuell
1,52 USD (49Mio Shares Outstanding)

Zeit
07.02.07 21:42

Diff. Vortag
+1,33 %

Tages-Vol.
172.751,60

Gehandelte Stück
114.853

Geld
1,51

Brief
1,53

Zeit
07.02.07 21:43

Spread
1,31%

Geld Stk.
6.500

Brief Stk.
100

[can2]

[can2]

Heute ist es so weit, schauen wir mal! ;=)

Tue, Feb 13, 2007

FILING An amendment to the SC 13G filing - Form SC 13G/A
FILING A statement of beneficial ownership of common stock by certain persons - Form SC 13G

Thu, Feb 01, 2007

8:04 AM Curis to Release Year End and Fourth Quarter 2007 Financial Results and Hold Conference Call on February 14, 2007 - Business Wire

Wed, Jan 31, 2007

8:10 AM Curis, Inc. Announces Dosing of First Patient in Hedgehog Antagonist Phase I Clinical Trial - Business